natgillin/translations-raw huggingface dataset:
Sanding element according to claim 8, characterised in that sanding grains (9) adhere to said fibres (10) by means of the above-mentioned synthetic resin. 
Element za brušenje u skladu s patentnim zahtjevom 8, naznačen time, što se zrnca za brušenje (9) prihvaćaju na navedena vlakna uz pomoć gore navedene sintetičke smole.
A method for making a compound of formula: comprising reacting a compound of formula: with a compound of formula: in the presence of EtOH, HCl, and DMF, wherein: 
Postupak dobivanja spoja [image], naznačen time što se postupak sastoji u reakciji spoja [image] sa spojem [image], u prisutnosti HCl, etanola i CH3O(CH2)2OH.
purifying the immunogenic portion. A polypeptide obtainable by the method of claim 1. The polypeptide of claim 2 comprising one, two, three or all four of amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5. 
Polipeptid koji se sastoji od aminokiselinskih odsječaka SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 i SEQ ID NO: 5, naznačen time, da su odsječak SEQ ID NO: 2 I odsječak 4 spojeni disulfidnom vezom na aminokiselinskim položajima 57 i 111 s referencom na odsječak SEQ ID NO: 1 a odsječci SEQ ID NO: 3 i 5 su spojeni
An antibody that is able to block binding of a binding compound to human IL-23 in a cross-blocking assay, wherein the binding compound comprises a light chain and a heavy chain, wherein the light chain comprises the sequence of SEQ ID NO: 14; and the heavy chain comprises a sequence selected from the group consisting of SEQ ID NOs: 6-8. 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 4, naznačeno time, što sadrži laki lanac i teški lanac, pri čemu: laki lanac sadrži sekvencu SEQ ID NO: 14; i teški lanac sadrži sekvencu SEQ ID NO: 7.
According to a preferred embodiment of the present invention the crosslinked polyethylene has a crosslinking degree of 20-90%. 
Sustav crpljenja sa šipkom prema bilo kojem od prethodnih zahtjeva, naznačen time da umreženi polietilen ima stupanj umreženosti od 20-90%,
A pocket spring mattress for use in a bedding or seating product, comprising a plurality of parallel strings of individually pocketed coil springs, wherein at least one of said individually pocketed coil springs is the individually pocketed coil spring of claim 1 . 
Madrac s ušivenim oprugama (1) za upotrebu u proizvodima za spavanje ili sjedenje, koji sadrži više paralelnih nizova (3) pojedinačno ušivenih spiralnih opruga (2), pri čemu je barem jedna, a po mogućnosti zapravo sve pojedinačno ušivene spiralne opruge sukladna bilo kojem od Zahtjeva 1-11.
a cost function based upon a least-squares difference between the stabilizing-torque and destabilizing-torque profiles; 
- < funkcije troškova koja se temelji na kriteriju razlike najmanjih kvadrata između profila stabilizirajućeg momenta i destabilizirajućeg momenta;
In one embodiment, the human gene encoding human IL-6 is a human IL-6 gene of BAC ID CTD-2369M23. In one embodiment, the mouse expresses a mouse IL-6Ra. 
Genetički modificirani miš prema zahtjevu 1, naznačen time da ljudski gen koji kodira ljudski IL-6 sadrži eksone 1 do 5 ljudskog II-6 gena pronađene u bakterijskom umjetnom kromosomu CTD-2369M23.
The method of claim 9 further comprising a method of preparing a compound of Formula IV, the method comprising: providing a compound of Formula V: wherein X3 is Cl, Br or I and 
Formula V pri čemu je X? Cl, Br ili I te tretiranja spoja Formule V s organometalnim reagensom koji sadrži organomagnezijev ili organolitijev spoj; time formirajući spoj Formule IV.
A compound of claim 6 or claim 7 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder in a mammal mediated by inhibition of protein tyrosine phosphatase PTP1B. 
Spoj sukladno zahtjevu 6 ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju poremećaja kod sisavaca posredstvom inhibicije protein-tirozin-fosfataze PTP1B.
The use according to claim 12, wherein said effective therapeutic amount of PLD is to be administered in a dosage of 30 mg/m2 over an infusion time of about 1 hour followed by said effective therapeutic amount of ET-743, to be administered in a dosage of 1.1 mg/m2 over an infusion time of about 3 hours. 
Primjena prema patentnom zahtjevu 12, naznačena time što će se navedena efikasna terapeutska količina PLD primjenjivati u dozi od 30 mg/m" u toku vremena infuzije od oko 1 sat nakon čega slijedi navedena efikasna terapeutska količina ET-743, koja će se primjenjivati u dozi od 1.1 mg/m" u toku vremena infuzije od oko 3 sata.
Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters of the formula wherein R1 is hydrogen or C1-6-alkyl, comprising the conversion of a 2-trifluoromethyl pyridine derivative of the formula wherein X is halogen or -OSO2CY3, wherein Y is halogen, with carbon monoxide (CO); in the presence of the reactant R1OH, wherein R1 is as above and in the presence of a palladium complex catalyst selected from Palladium(II)chloride with the ligand 1,1'-Bis-(diphenylphosphino)ferrocen (dppf). 
CF, pri čemu R' predstavlja vodik ili C,«-alkil i obuhvaća konverziju 2-trifluorometil piridin derivata prema sljedećoj formuli: X x il £ NC gdje X predstavlja halogen ili -OSO;CY:, dok Y je halogen, s ugljičnim monoksidom (CO); u prisutnosti reaktanta R'OH, pri čemu R' ima značenje koje je gore navedeno i u prisutnosti paladijevog kompleksa koji djeluje kao katalizator odabran iz paladij(ID)klorida s ligandom 1,1'-Bis-(difenilfosfino)ferocen (dfff).
The method of claim 7, wherein the nucleic acid is introduced into the plant in a transient manner or wherein, the nucleic acid is stably integrated within a genome of the plant. 
Postupak sukladno patentnom zahtjevu 1, naznačen time, da se nukiemska kiselina uvodi u biljku na prijelazni način ili gdje je nuklemska kiselma stabilno integrirana unutar genoma biljke.
The compound of claim 1, for use in the treatment of diabetes, wherein the compound is administered once weekly or less frequently, and, on average, during a period of time of at least 1 month, 6 months or 1 year, said compound is not administered more frequently to the same patient. 
Spoj prema patentnom zahtjevu 1, za uporabu u liječenju dijabetesa, naznačeno time da je spoj primjenjen jednom tjedno, ili rjeđe, 1, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
The method of any preceding claim, wherein the bag (20) is filled with a sample through an aperture (25,26), the aperture is sealed and the sample in the bag is frozen. 
(20) stavlja kroz otvor (25, 26), zatim se otvor hermetički zatvara,a a uzorak u navedenoj vrećici se zamrzava.
A compound according to claim 1, wherein the compound is 3,4-dihydroxy-3',4'-dimethylbiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, daje spoj 3,4-dihidroksi-3',4'-dimetilbi fenil-2,6- dikarbonitril.
A method comprising the step detecting in a sample from a subject the presence of an antibody to Ara h 7 isotype 7.0201, preferably to SEQ ID NO 6, more preferably to a sequence from the group comprising SEQ ID NO7, SEQ ID NO8, SEQ ID NO9 and SEQ ID NO10, most preferably SEQ ID NO8. 
Postupak za dijagnozu alergije na kikiriki naznačen time što obuhvaća korak otkrivanja u uzorku od subjekta prisutnosti protutijela na epitopu C-terminalnog kraja Ara h 7 izotipa 7.0201, pri čemu C-terminalni kraj sadrži SEQ ID NO 6 i pri čemu epitop sadrži SEQ ID NO 8.
determining whether the compound stimulates GLP-1 secretion from the mammalian enteroendocrine cell; wherein the ability of the test compound to stimulate GLP-1 secretion from the mammalian enteroendocrine cell is further indicative of the test compound being a GLP-1 secretagogue. 
(e) određivanje da li spoj stimulira GLP-1 sekreciju iz enteroendokrine stanice sisavca; pri čemu je sposobnost test spoja da stimulira GLP-! sekreciju iz enteroendokrine stanice sisavca nadalje indikativna da je test spoj GLP-1 sekretogog.
The method for producing a nicotine-containing granulate according to claim 1, wherein prior to the mixing in step (a), sweeteners, binding agents, separating agents, lubricants, coloring agents, flavor additives, acids, effervescent agents, antioxidants, glidants and/or preservatives are added. A nicotine-containing granulate that is obtained by the method of claim 1 . 
Postupak dobivanja granulata koji sadrži nikotin u skladu s bilo kojim od patentnih zahtjeva 4 do 8, naznačen time što se sladila, veziva, sredstva za razdvajanje, maziva, bojila, arome, kiseline, pjenila, antioksidante, sredstva za kliženje i/ili konzervanse pomiješa s drugim komponentama u koraku (a).
A bispecific antibody or bispecific antibody fragment thereof that specifically binds to IL-13 and IL-4, wherein said bispecific antibody or bispecific antibody fragment thereof contains two light chains with the structure N-VLhB-B13-linker-VLhBD4-8-CL-C and two heavy chains with the structure N-VHhB-813-linker-VHhBD4-8-CH1-CH2-CH3-C, wherein VLhB-B13 comprises amino acid sequence SEQ ID NO: 1, wherein VLh8D4-3 comprises amino acid sequence SEQ ID NO: 3, wherein VHhB-B13 comprises amino acid sequence SEQ ID NO: 2, wherein VHh8D4-8 comprises amino acid sequence SEQ ID NO: 5, and wherein each linker is a peptide linker having an amino acid sequence consisting of SEQ ID NO: 6. 
Bispecifično protutijelo ili njegov fragment protutijela koje se specifično veže na IL-13 i IL-4, pri čemu bispecifično protutijelo ili njegov fragment protutijela sadrži dva laka lanca sa strukturom N-VLhB-B13-poveznica-VLh8D4-8-CL-C i dva teška lanca sa strukturom N-VHhB-B13-poveznica-VHh8D4-8-CH1-CH2-CH3-C, pri čemu CL je konstantna regija lakog lanca, VLhB-B13 je humanizirana varijabilna domena lakog lanca od anti IL-13 protutijela B-B13, VLh8D4-8 je humanizirana varijabilna domena lakog lanca od anti IL-4 protutijela 8D4-8, VHhB-B13 je humanizirana varijabilna domena teškog lanca od anti IL-13 protutijela B-B13, i VHh8D4-8 je humanizirana varijabilna domena teškog lanca od anti IL-4 protutijela 8D4-8;
A method according to any one of 28 to 30 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću P1I3-kinaze astma, kronična opstruktivna plućna bolest (COPD), idiopatska plućna fibroza (IPF), virusne infekcije dišnog sustava, virusne komplikacije respiratornih bolesti, aspergiloza, lišmenijaza, alergičko rinitis, atopični dermatitis, reumatoidni artritis, multipla skleroza, upalna bolest crijeva, tromboza, ateroskleroza, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bolest bubrega, agregacija trombocita, rak, pokretljivost sperme, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, bol povezana s reumatoidnim artritisom ili osteoartritisom, bol u leđima, opća upalna bol, posthepatična neuralgija, dijabetična neuropatija, upalna neuropatska bol (trauma), trigeminalna neuralgija ili centralna bol.
preparing a compound of formula 3 via arylation of a compound of formula 4 with a compound of formula R1-H; 
pripravu spoja s formulom 3 putem arilacije spoja s formulom 4 sa spojem s formulom R1-H;
The halogen-substituted phenyl groups include, for example, the phenyl group(s) as mentioned above having 1 to 7, preferably 1 to 3, halogen atom(s) as a substituent(s). 
(Alc) amino skupinu koja ima fenilnu skupinu s halogcn-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (s) na fenilnoj skupini, te skupinu niži alkil, ili
CRL-9096 (CHOdhfr-); and/or an amount of G2 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 50% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from ATCC No. 
CRL-9096 (CHOdhfr-); i/ili (ii) količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 50% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
The present composition is particularly suitable for preventing light induced flavour changes in beverages and foodstuffs that contain significant quantities of riboflavin, which substance can act as a photo-initiator. 
Sadašnji pripravak je naročito prikladan za sprečavanje promjena arome induciranih svjetlom u pićima i prehrambenim proizvodima koji sadržavaju veće količine riboflavina, koja tvar može djelovati kao foto-pokretač.
The reactor (3; 3 ′) as claimed in claim 9 wherein the heating means is resistor heater, air fan heating, infrared heater or microwave heater or combination thereof. 
Reaktor (3, 3'), prema zahtjevu 9, naznačen time da je dio aparature za zagrijavanje može biti grijač s otpornicima, grijač sa zračnim puhačem, infracrveni grijač ili mikrovalni grijač 1li kombinacija navedenih grijača.
A seismic clip as set forth in claim 1, wherein the lanced tab is spaced from the plane of the wings by a distance of about ¾ inch. 
Seizmička spajalica kako je određena prethodno u patentnom zahtjevu 1, pri čemu je isturena pločica (43) razmaknuta od ravnine krila s udaljenošću od približno 1,9 cm.
when the fusion protein is administered to a subject less frequently in comparison to the corresponding growth hormone that lacks the XTEN administered to a subject using an otherwise equivalent molar amount, the fusion protein achieves a comparable area under the curve (AUC) as the corresponding growth hormone that lacks the XTEN; 
(iii) kada se fuzijski protein primjenjuje na pojedincu smanjenom učestalošću u usporedbi s odgovarajućim GH kojemu nedostaje XTEN, a koji se primjenjuje na pojedincu korištenjem neke druge ekvivalentne molarne količine, tada fuzijski protein postiže usporedivu površinu ispod krivulje (AUC) u usporedbi s odgovarajućim GH kojemu nedostaje XTEN;
The insulators have a thermal conductivity in g-cal/(sec) (cm²)(°C,/cm), of less than about 0.05, preferably less than about 0.02, most preferable less than about 0.005. 
HR P950147 B1 Izolatori imaju termičku provodijivost u g-cal/(s)(cm?)X(*C/em) manju od oko 0,05, poželjno manju od oko 0.02, najpoželjnije manju od oko 0.005.
Moreover a urea plant that contains this vessel is very high. The object of the invention is to overcome these disadvantages. The invention is characterized in that the flow of the first synthesis solution from the first reactor section to the second reactor section, the flow of the second synthesis solution from the second reactor section to the stripper, the flow of the mixed gas stream from the stripper to the condenser and of the condensate from the condenser to the first reactor section is a gravity flow. 
-istruja uree koja se dobiva u ekstrahatoru dalje pročišćava u odjeljku za regeneraciju, 2) naznačen time što je protok prve otopine sinteze od prvog reaktorskog odjeljka prema drugom reaktorskom odjeljku, protok druge otopine sinteze iz drugog odjeljka reaktora prema ekstrahatoru, protok mješovitog plina od ekstrahatoru prema kondenzatoru i protok kondenzata od kondenzatora prema prvom reaktorskom odjeljku je tlak gravitacije, h) pri čemu su prvi odjeljak reaktora i kondenzator spajaju u jednoj posudi, pri čemu je ta posuda postavljena vodoravno, i)
A structure according to claim 1, wherein the location of each anchor point is located below the normal waterline of the craft. 
Plovilo sposobno za morsku plovidbu u skladu sa patentnim zahtjevom 5, gdje je lokacija svake točke za sidrenje (12) locirana ispod normalne linije vode plovila (2).
The solution was filtered and the solid was collected and air dried overnight to give the title compound, 1-(6-chloro-4,5-bis(4-chlorophenyl)pyridazin-3-yl)hydrazine (3.7gm, 83% yield) as a solid. 
Otopina je filtrirana i krutina je sakupljena i osušena strujanjem zraka tijekom noći pri čemu se dobiva spoj iz naslova, 1-(6- kloro-4,5-bis(4-klorofenil)piridazin-3-il)hidrazin (3.7 mg, 83% prinos) kao krutina.
A method of treating a viral, bacterial, fungal, or parasitic infection in an animal comprising administering an effective amount of a compound having the formula N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof, to the animal. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 4 do 6, naznačen time da antigen je virusno cjepivo. Uporaba spoja koji ima formulu N-(4-{[4-amino-2-butil-1H-imidazo[4,5-c]kinolin-1-il]oksi}butil)oktadekanamid, ili njegova farmaceutski prihvatljiva sol, naznačena time da je adjuvant za cjepivo.
a heat exchanger configured to provide cooling and heating for an air conditioning system of the vehicle; 
izmjenjivač topline (210) konfiguriran tako da omogućava hlađenje i grijanje za klimatizacijski sustav kabine;
The lower inner element 14 furthermore comprises two holding members 28 which are adapted to hold an element e.g. a booklet comprising information about the optical storage medium. 
Donji unutarnji element 14 nadalje sadržava dva elementa za držanje 28 koji su prilagođeni tako da drže neki element, na primjer, knjižicu koja sadržava informacije o optičkom sredstvu koje se pohranjuje.
A method for treating or delaying the progression or onset of a disease selected from diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, and hypertension, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound having the following structure: 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa melitusa, dijabetične retinopatije, dijabetične neuropatije, dijabetične nefropatije, usporenog zarastanja rana, otpornosti na inzulin, hiperglikemije, hiperinzulinemije, povišenih razina masnih kiselina u krvi, povišenih razina glicerola u krvi, hiperlipidemije, pretilosti, hipertrigliceridemije, Sindroma X, komplikacija dijabetesa, ateroskleroze ili hipertenzije.
Use according to claim 12 wherein the polymorphic Form B of N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide is in a dose from 5 to 10 mg/kg. A polymorphic Form B of N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide according to claim 1 or 2 for use in the treatment of drug addiction and alcoholism. 
Polimorfni oblik A N-[4-(trifluorometil)benzil]-4-metoksibutiramida, za primjenu u skladu sa zahtjevom 13, naznačen time što je polimorfni oblik A N-[4-(trifluorometil)benzil]-4-metoksibutiramida u dozi od 5 do 10 mg/kg.
A hand held medicine dosing and dispensing device according to Claim 17 wherein the feed wheel includes a plurality of equidistantly spaced fins protruding outwardly from its outer circumference, adjacent fins defining the feed pockets therebetween such that rotation of the feed wheel in the first direction moves each of the fins sequentially into engagement with a front face of the second end of the impacter and continued rotation of the feed wheel causes deflection of the second end of the impacter towards the wall of the storage chamber as the respective fin is moved across the front face of the second end of the impacter and out of engagement therewith. 
Ručni uređaj za doziranje 1 izdavanje lijeka prema zahtjevu 17 naznačen time da dobavni kotačić sadrži veći broj u jednakim razmacima razmaknutih rebara koja strše prema van iz njegovog vanjskog oboda, susjedna rebra između njih definiraju džepove za dopremanje tako da rotacija dobavnog kotačića u prvom smjeru pomiče svako od rebara uzastopno u zahvat s prednjom stranom drugog kraja udarača i kontinuirana rotacija dobavnog kotačića uzrokuje otklon drugog kraja udarača sprema stjenki komore za pohranjivanje dok se odgovarajuće rebro pomiče duž prednje strane drugog kraja udarača i izvan zahvata s njim.
Glatiramer acetate for use in a regimen for treating a human patient suffering from a relapsing form of multiple sclerosis which regimen consists of subcutaneous injections for at least 6 months of 1ml of a pharmaceutical composition comprising 40mg of glatiramer acetate on only three days during each week with at least one day without a subcutaneous injection of the pharmaceutical composition between each day on which there is a subcutaneous injection, wherein the pharmaceutical composition is in a prefilled syringe, and wherein the pharmaceutical composition further comprises mannitol and has a pH in the range 5.5 to 7.0. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu u liječenju čovjeka kao pacijenta koji pati od relapsirajućeg oblika multiple skleroze, naznačen time, da se daje u režimu od tri supkutane injekcije dozom od po 40 mg glatiramer acetata svakog tjedna s barem jednim danom između svake supkutane injekcije i u čemu farmaceutski sastav nadalje sadrži manitol i ima pH u području od 5,5 do 7,0.
Embodiment 34. The controlled release pharmaceutical composition according to embodiment 33, wherein the amount in a dosage form is 90, 120, 180, 240 or 360 mg active substance. 
Sastav za kontrolirano otpuštanje u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je količina dimetilfumarata u obliku doziranja između 90 mg i 360 mg aktivne tvari.
represents a hydrogen atom, a fluoro atom, a chloro atom, or a bromo atom; 
predstavlja vodikov atom, fluorov atom, klorov atom, ili bromov atom;
Composition according to claim 1, characterised in that the basic amino acid is L-arginine. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je bazična aminokiselina L-arginin.
Current sensor according to claim 7, characterised in that the data transmission arrangement comprises an optical transmitter (55) to transmit the data representing the value of the current (I) at the high voltage line (13). 
Strujni senzor u skladu s patentnim zahtjevom 7, naznačen time, da uređaj za prijenos podataka sadrži optički prijenosnik (55) za prijenos podataka koji predstavljaju vrijednost struje (1) kod visokonaponskog voda (13).
Y is a bond, O, CH2, or NH; or a pharmaceutically acceptable salt thereof. 
Y je veza, O, CH, ili NH; ili njegova farmaceutski prihvatljiva sol.
The bacterial species Roseburia hominis for use in treating a disorder selected from an inflammatory disorder, an immune disorder and an intestinal disorder in a subject. 
Bakterijska vrsta Roseburia hominis za upotrebu prema zahtjevu 1 naznačena time što je bakterija za upotrebu u liječenju poremećaja odabranog od upalnog poremećaja, imunog poremećaja 1 crijevnog poremećaja kod subjekta.
Pharmaceutical composition comprising pantoprazole as the active ingredient having the form of a tablet comprising 
Farmaceutski sastav koji obuhvaća pantoprazol kao djelatni sastojak u obliku tablete 1 obuhvaća sljedeće: